[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Metavia Inc (MTVA)

Metavia Inc (MTVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,986
  • Shares Outstanding, K 5,164
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,970 K
  • EBIT $ -14 M
  • EBITDA $ -14 M
  • 60-Month Beta 0.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.85
  • Number of Estimates 2
  • High Estimate $-0.83
  • Low Estimate $-0.87
  • Prior Year $-2.86
  • Growth Rate Est. (year over year) +70.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9710 +79.20%
on 05/13/26
4.3100 -59.63%
on 05/22/26
+0.7700 (+79.38%)
since 05/12/26
3-Month
0.9661 +80.11%
on 05/12/26
4.3100 -59.63%
on 05/22/26
+0.1300 (+8.07%)
since 03/12/26
52-Week
0.9661 +80.11%
on 05/12/26
19.0289 -90.86%
on 09/15/25
-6.5100 (-78.91%)
since 06/12/25

Most Recent Stories

More News
BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

POMPANO BEACH, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization...

BSEM : 4.0800 (+21.43%)
MTVA : 1.7400 (-13.43%)
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

DA-1726 Phase 1, 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau

MTVA : 1.7400 (-13.43%)
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

CAMBRIDGE, Mass. , June 4, 2026 /PRNewswire/ --  MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung...

MTVA : 1.7400 (-13.43%)
MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau

MTVA : 1.7400 (-13.43%)
MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH

CAMBRIDGE, Mass. , May 20, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the publication...

MTVA : 1.7400 (-13.43%)
MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions

Three Late-Breaking Posters Highlight DA-1726, a GLP-1 /Glucagon Dual Agonist, and Vanoglipel, a GPR119 Agonist

MTVA : 1.7400 (-13.43%)
MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update

48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit

MTVA : 1.7400 (-13.43%)
MetaVia Moves DA-1726 Into Higher-Dose Territory as Phase 1 Data Build a Compelling Obesity Case

MetaVia Inc. has dosed the first patient in the third part of its Phase 1 trial for DA-1726, a dual-receptor obesity candidate designed to outperform standard GLP-1 agonists by increasing energy expenditure...

MTVA : 1.7400 (-13.43%)
MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026

CAMBRIDGE, Mass. , May 11, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that a late-breaking...

MTVA : 1.7400 (-13.43%)
MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity

16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults

MTVA : 1.7400 (-13.43%)

Business Summary

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 2.4833
2nd Resistance Point 2.3267
1st Resistance Point 2.0333
Last Price 1.7400
1st Support Level 1.5833
2nd Support Level 1.4267
3rd Support Level 1.1333

See More

52-Week High 19.0289
Fibonacci 61.8% 12.1289
Fibonacci 50% 9.9975
Fibonacci 38.2% 7.8661
Last Price 1.7400
52-Week Low 0.9661

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.